articleThe LancetOct 20, 2015Closed access

Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial

University of Lübeck · University Hospital Schleswig-Holstein · +12 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

566
total citations
FWCI
62.50
Percentile
100%
References
35
Citations per year

Authors

21

Topics & keywords

Keywords
  • Eczema Area and Severity Index
  • Dupilumab
  • Medicine
  • Atopic dermatitis
  • Blinding
  • Placebo
  • Dermatology Life Quality Index
  • Randomized controlled trial
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding